CR9918A - Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina - Google Patents

Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina

Info

Publication number: CR9918A
Authority: CR; Costa Rica
Prior art keywords: antigonist; pirazolo; pyrimidinyl; alpha; derivatives
Prior art date: 2005-09-30

Application number

CR9918A

Other languages

English (en)

Inventor

Frank Hossner

Original Assignee

Neurocrine Biosciences Inc

Bayer Cropsciense Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-30

Filing date

2008-04-23

Publication date

2009-02-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-23 Application filed by Neurocrine Biosciences Inc, Bayer Cropsciense Ag filed Critical Neurocrine Biosciences Inc

2009-02-03 Publication of CR9918A publication Critical patent/CR9918A/es

Links

-1 PYRIMIDINYL Chemical class 0.000 title 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
239000003488 releasing hormone Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CR9918A 2005-09-30 2008-04-23 Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina CR9918A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0519957.5A GB0519957D0 (en)	2005-09-30	2005-09-30	Chemical compound

Publications (1)

Publication Number	Publication Date
CR9918A true CR9918A (es)	2009-02-03

Family

ID=35395069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR9918A CR9918A (es)	2005-09-30	2008-04-23	Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina

Country Status (21)

Country	Link
US (1)	US7879862B2 (es)
EP (2)	EP1802627B1 (es)
JP (2)	JP4901744B2 (es)
KR (2)	KR20070088621A (es)
CN (1)	CN101273043B (es)
AR (2)	AR051461A1 (es)
AU (2)	AU2005295353B2 (es)
BR (1)	BRPI0616767A2 (es)
CA (2)	CA2584567C (es)
CR (1)	CR9918A (es)
EA (1)	EA200801000A1 (es)
GB (1)	GB0519957D0 (es)
IL (1)	IL190225A0 (es)
MA (1)	MA29850B1 (es)
NO (2)	NO20072541L (es)
NZ (1)	NZ554082A (es)
PE (2)	PE20060586A1 (es)
RU (1)	RU2007118683A (es)
TW (2)	TW200626599A (es)
UA (1)	UA92756C2 (es)
WO (2)	WO2006044958A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY143499A (en) *	2003-12-22	2011-05-31	Sb Pharmco Inc	Crf receptor antagonist and methods relating thereto
GB0519957D0 (en) *	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7579360B2 (en)	2005-06-09	2009-08-25	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en)	2005-06-09	2009-08-11	Bristol-Myers Squibb Company	Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en)	2005-09-30	2012-01-03	Smithkline Beecham (Cork) Limited	Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
US8119658B2 (en)	2007-10-01	2012-02-21	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101932583A (zh)	2007-12-19	2010-12-29	沃泰克斯药物股份有限公司	用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
EP2266990B1 (en) *	2008-04-15	2012-09-26	Eisai R&D Management Co., Ltd.	3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
EP2487177A1 (en) *	2009-10-08	2012-08-15	Eisai R&D Management Co., Ltd.	Pyrazoloxazole compound
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja)	2010-02-01	2013-05-20	ノバルティスアーゲー	ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja)	2010-02-02	2015-07-15	ノバルティスアーゲー	Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
UY34094A (es)	2011-05-27	2013-01-03	Novartis Ag	Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
WO2013074641A1 (en)	2011-11-16	2013-05-23	Array Biopharma Inc.	Piperidinyl- substituted cyclic ureas as gpr119 modulators
US20150094310A1 (en) *	2012-04-23	2015-04-02	Holsboermaschmeyer Neurochemie Gmbh	Crhr1 antagonists for use in the treatment of patients having crh overactivity
CA2867043A1 (en)	2012-05-03	2013-11-07	Novartis Ag	L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
GB201210686D0 (en)	2012-06-15	2012-08-01	Holsboermaschmeyer Neurochemie Gmbh	V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en)	2013-06-17	2013-07-31	Max Planck Innovation Gmbh	Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
RS65839B1 (sr)	2014-01-21	2024-09-30	Neurocrine Biosciences Inc	Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
JP6509238B2 (ja) *	2014-01-22	2019-05-08	キュロヴィル・アクチボラグ	治療に有用なピラゾロ［１，５−ａ］ピリミジン−７−アミン誘導体
CN110446495B (zh)	2017-02-17	2023-09-05	特维娜有限公司	含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
WO2018165520A1 (en)	2017-03-10	2018-09-13	Vps-3, Inc.	Metalloenzyme inhibitor compounds
US20220023266A1 (en)	2018-12-07	2022-01-27	Neurocrine Biosciences, Inc.	Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
AU2020321955A1 (en)	2019-07-30	2022-03-17	Eikonizo Therapapeutics, Inc.	HDAC6 inhibitors and uses thereof
JP7623365B2 (ja)	2019-09-27	2025-01-28	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
MX2022007376A (es)	2019-12-20	2022-09-02	Tenaya Therapeutics Inc	Fluoroalqull-oxadiazoles y sus usos.
WO2022093904A1 (en) *	2020-10-27	2022-05-05	Trevena, Inc.	Crystalline and amorphous forms of a delta-opioid modulator
US20240252502A1 (en)	2021-05-04	2024-08-01	Tenaya Therapeutics, Inc.	Hdac6 inhibitors for treatment of metabolic disease and hfpef
TW202345813A (zh)	2022-04-08	2023-12-01	美商艾科尼佐療法股份有限公司	㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4605642A (en)	1984-02-23	1986-08-12	The Salk Institute For Biological Studies	CRF antagonists
WO1995035298A1 (en)	1994-06-21	1995-12-28	Otsuka Pharmaceutical Factory, Inc.	PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
US6664261B2 (en)	1996-02-07	2003-12-16	Neurocrine Biosciences, Inc.	Pyrazolopyrimidines as CRF receptor antagonists
AU713673B2 (en)	1996-02-07	1999-12-09	Neurocrine Biosciences Inc.	Pyrazolopyrimidines as crf receptor antagonists
HU229024B1 (en)	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
EA004403B1 (ru) *	1996-07-24	2004-04-29	Дюпон Фармасьютикалз Компани	Производные пиразолотриазинов, фармацевтические композиции, содержащие их, способы лечения
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
JPH10101672A (ja)	1996-08-06	1998-04-21	Otsuka Pharmaceut Factory Inc	アデノシン増強剤
JPH10101671A (ja)	1996-08-08	1998-04-21	Otsuka Pharmaceut Factory Inc	一酸化窒素合成酵素阻害剤
JP3621706B2 (ja)	1996-08-28	2005-02-16	ファイザー・インク	置換された６，５―ヘテロ―二環式誘導体
ATE301657T1 (de) *	1998-01-28	2005-08-15	Bristol Myers Squibb Pharma Co	Azolo-pyrimidine
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
WO2000044754A1 (en)	1999-01-29	2000-08-03	Sumitomo Chemical Company, Limited	Fat accumulation inhibitory agents
AU4203500A (en) *	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
CA2379585C (en)	1999-09-30	2006-06-20	James W. Darrow	Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
ES2277855T3 (es)	1999-09-30	2007-08-01	Neurogen Corporation	Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
CO5271670A1 (es) *	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
DE60225127T2 (de) *	2001-04-30	2009-02-19	Glaxo Group Ltd., Greenford	Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
EP1395591B1 (en) *	2001-06-12	2008-06-04	Glaxo Group Limited	Corticotropin releasing factor antagonists
GB0117396D0 (en) *	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
AU2003240488A1 (en)	2002-06-04	2003-12-19	Neogenesis Pharmaceuticals, Inc.	Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
WO2004062665A1 (en) *	2003-01-16	2004-07-29	Sb Pharmco Puerto Rico Inc	Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists
US20070179161A1 (en)	2003-03-31	2007-08-02	Vernalis (Cambridge) Limited.	Pyrazolopyrimidine compounds and their use in medicine
US20070021429A1 (en) *	2003-04-09	2007-01-25	Yves St-Denis	Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) *	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
JP2007515474A (ja)	2003-12-22	2007-06-14	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
MY143499A (en)	2003-12-22	2011-05-31	Sb Pharmco Inc	Crf receptor antagonist and methods relating thereto
DE102004008807A1 (de) *	2004-02-20	2005-09-08	Bayer Cropscience Ag	Pyrazolopyrimidine
US7652035B2 (en) *	2004-10-19	2010-01-26	Neurocrine Bioscience, Inc.	CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) *	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US8088779B2 (en) *	2005-09-30	2012-01-03	Smithkline Beecham (Cork) Limited	Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

2005
- 2005-09-30 GB GBGB0519957.5A patent/GB0519957D0/en not_active Ceased
- 2005-10-17 PE PE2005001219A patent/PE20060586A1/es not_active Application Discontinuation
- 2005-10-17 TW TW094136095A patent/TW200626599A/zh unknown
- 2005-10-17 AR ARP050104337A patent/AR051461A1/es not_active Application Discontinuation
- 2005-10-19 AU AU2005295353A patent/AU2005295353B2/en not_active Ceased
- 2005-10-19 CA CA2584567A patent/CA2584567C/en not_active Expired - Fee Related
- 2005-10-19 NZ NZ554082A patent/NZ554082A/en not_active IP Right Cessation
- 2005-10-19 KR KR1020077008794A patent/KR20070088621A/ko not_active Ceased
- 2005-10-19 JP JP2007537996A patent/JP4901744B2/ja not_active Expired - Lifetime
- 2005-10-19 WO PCT/US2005/037576 patent/WO2006044958A1/en not_active Ceased
- 2005-10-19 RU RU2007118683/04A patent/RU2007118683A/ru not_active Application Discontinuation
- 2005-10-19 EP EP05818308A patent/EP1802627B1/en not_active Expired - Lifetime
- 2005-10-19 US US11/576,957 patent/US7879862B2/en active Active
2006
- 2006-09-28 AU AU2006298995A patent/AU2006298995B2/en not_active Ceased
- 2006-09-28 PE PE2006001185A patent/PE20070845A1/es not_active Application Discontinuation
- 2006-09-28 EP EP06805979A patent/EP1934222B1/en active Active
- 2006-09-28 JP JP2008532687A patent/JP2009510004A/ja not_active Ceased
- 2006-09-28 EA EA200801000A patent/EA200801000A1/ru unknown
- 2006-09-28 KR KR1020087007620A patent/KR20080063760A/ko not_active Withdrawn
- 2006-09-28 WO PCT/EP2006/009531 patent/WO2007039264A1/en not_active Ceased
- 2006-09-28 UA UAA200803939A patent/UA92756C2/ru unknown
- 2006-09-28 BR BRPI0616767-5A patent/BRPI0616767A2/pt not_active IP Right Cessation
- 2006-09-28 TW TW095135886A patent/TW200745121A/zh unknown
- 2006-09-28 AR ARP060104269A patent/AR056104A1/es not_active Application Discontinuation
- 2006-09-28 CN CN2006800355977A patent/CN101273043B/zh not_active Expired - Fee Related
- 2006-09-28 CA CA002624699A patent/CA2624699A1/en not_active Abandoned
2007
- 2007-05-16 NO NO20072541A patent/NO20072541L/no not_active Application Discontinuation
2008
- 2008-03-17 IL IL190225A patent/IL190225A0/en unknown
- 2008-04-04 MA MA30813A patent/MA29850B1/fr unknown
- 2008-04-23 NO NO20081941A patent/NO20081941L/no not_active Application Discontinuation
- 2008-04-23 CR CR9918A patent/CR9918A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20060586A1 (es)	2006-09-20
CA2584567A1 (en)	2006-04-27
EP1934222B1 (en)	2012-07-25
WO2006044958A8 (en)	2006-06-08
MA29850B1 (fr)	2008-10-03
TW200745121A (en)	2007-12-16
WO2006044958A1 (en)	2006-04-27
RU2007118683A (ru)	2008-11-27
BRPI0616767A2 (pt)	2011-06-28
TW200626599A (en)	2006-08-01
JP4901744B2 (ja)	2012-03-21
JP2008517067A (ja)	2008-05-22
JP2009510004A (ja)	2009-03-12
US20080194589A1 (en)	2008-08-14
KR20070088621A (ko)	2007-08-29
AU2005295353A1 (en)	2006-04-27
US7879862B2 (en)	2011-02-01
NZ554082A (en)	2010-12-24
PE20070845A1 (es)	2007-08-25
EP1802627A1 (en)	2007-07-04
GB0519957D0 (en)	2005-11-09
CA2584567C (en)	2013-04-30
CA2624699A1 (en)	2007-04-12
AU2006298995B2 (en)	2012-06-14
EA200801000A1 (ru)	2009-02-27
IL190225A0 (en)	2009-09-22
EP1934222A1 (en)	2008-06-25
AU2005295353B2 (en)	2012-01-12
AR056104A1 (es)	2007-09-19
CN101273043A (zh)	2008-09-24
KR20080063760A (ko)	2008-07-07
AU2006298995A1 (en)	2007-04-12
NO20081941L (no)	2008-04-23
CN101273043B (zh)	2011-08-03
UA92756C2 (ru)	2010-12-10
NO20072541L (no)	2007-06-25
WO2007039264A1 (en)	2007-04-12
EP1802627B1 (en)	2012-08-29
AR051461A1 (es)	2007-01-17

Legal Events

Date	Code	Title	Description
2013-04-05	FA	Abandonment or withdrawal (granting procedure)

Publication	Publication Date	Title
CR9918A (es)	2009-02-03	Derivados de pirazolo[1,5-alfa]pirimidinilo utiles como antagonistas de receptor de factor liberador de corticotropina
MA28824B1 (fr)	2007-08-01	Derives de pyrimidine
MA28813B1 (fr)	2007-08-01	Derives de pyrimidine
IL188725A0 (en)	2008-08-07	Pyrazine derivatives useful as adenosine receptor antagonists
BRPI0716936A2 (pt)	2013-09-17	derivados de adenosina como antigonistas de receptor de a2a
NL2000323A1 (nl)	2007-06-21	Pyrimidine-derivaten.
EP1724267A4 (en)	2009-04-22	pyrimidine derivative
CU23886B1 (es)	2013-04-19	Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
EP2154967A4 (en)	2010-05-19	Pyrimidine derivatives
ATE481409T1 (de)	2010-10-15	Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
BRPI0911688A2 (pt)	2015-07-28	"compostos de pirimidina, composições e métodos de uso"
DOP2007000068A (es)	2007-10-31	Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
EP1890703A4 (en)	2010-11-03	pyrimidine
DK1995242T3 (da)	2012-12-17	Hidtil ukendt 1,2,3,4-tetrahydroquinoxalinderivat med glucocorticoidreceptorbindingsaktivitet.
IL185912A0 (en)	2008-01-06	Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
ZA200800320B (en)	2009-02-25	Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
CR20130209A (es)	2013-09-19	Derivados de carboxamida como antagonistas del receptor muscarinico
GB0525083D0 (en)	2006-01-18	Pyrimidine derivatives
ATE454377T1 (de)	2010-01-15	2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE538130T1 (de)	2012-01-15	Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
DE602006010508D1 (de)	2009-12-31	Substituierte triazolderivate als oxytocinantagonisten
ATE487718T1 (de)	2010-11-15	Substituierte bizyklische pyrimidonderivate
PT1355639E (pt)	2006-06-30	Derivados de carboestirilo substituidos como agonistas do subtipo de receptores 5-ht1a
ATE449080T1 (de)	2009-12-15	4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
ATE513817T1 (de)	2011-07-15	Pyrimidinderivate und ihre verwendung als pestizide